Aadi Bioscience, Inc.

NasdaqCM:AADI Stock Report

Market Cap: US$46.5m

Aadi Bioscience Balance Sheet Health

Financial Health criteria checks 6/6

Aadi Bioscience has a total shareholder equity of $78.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $101.6M and $22.8M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$78.57m
EquityUS$78.79m
Total liabilitiesUS$22.83m
Total assetsUS$101.62m

Recent financial health updates

Recent updates

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Jul 03
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Jul 02
Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

May 10
Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07
Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12
Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16
Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10
Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Sep 28
A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Sep 21

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Jul 06
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Jun 23

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27
What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

Financial Position Analysis

Short Term Liabilities: AADI's short term assets ($93.0M) exceed its short term liabilities ($22.1M).

Long Term Liabilities: AADI's short term assets ($93.0M) exceed its long term liabilities ($682.0K).


Debt to Equity History and Analysis

Debt Level: AADI is debt free.

Reducing Debt: AADI had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AADI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AADI has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 42.5% each year.


Discover healthy companies